Vaccinex’s mission is to deliver innovative therapies that improve the lives of patients and provide treatment solutions for critical unmet needs. Through deep understanding of science and pathology of disease, we are pioneering a differentiated approach to treating neurologic diseases and cancer with novel antibody therapeutics. We are grateful to the patients, families, and the clinical staff that participate in our clinical trials. Each individual’s participation contributes to the potential to realize benefits for patients today and to advance our understanding of disease for the next generation.

Product Pipeline

Click to download


Clinical trials evaluating pepinemab for the treatment of neurologic diseases including Alzheimer’s Disease

Active, not recruiting

SIGNAL-AD Alzheimer’s Disease
Evaluating the Safety and Efficacy of our drug Pepinemab in Patients with Alzheimer’s Disease.
Phase 1b/2

Condition(s) Alzheimer Disease (AD)


Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation

To learn more about the details of this trial, select your role:


SIGNAL Huntington's Disease
Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of our drug Pepinemab in Patients with Late Prodromal and Early Manifest Huntington Disease.
Phase 2

Condition(s) Huntington's Disease


Click for more information about our Neurology Programs